Scientist (Translational Biomarkers & Immunomonitoring)

Job Description About the Company: BriaCell Therapeutics is a clinical-stage immuno-oncology company developing novel cell-based immunotherapies for solid tumors, including metastatic breast cancer. Our mission is to advance innovative immunotherapy approaches that improve outcomes for patients with difficult-to-treat malignancies. Bria-IMTTM, BriaCell’s lead candidate, was awarded Fast Track status by FDA and is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC). MBC is breast cancer that has spread to other tissues. Bria-IMTTM is a targeted cell-based immunotherapy. Bria-OTSTM, a platform of personalized off-the-shelf cell-based immunotherapies, is being evaluated in a Phase 1/2 clinical study initially targeting breast cancer, with extension to prostate cancer, and other cancers. Learn more at: BriaCell | Advancing Cancer Immunotherapy Treatment About the Position: We are seeking a motivated Scientist, Translational Biomarkers & Immunomonitoring to support biomarker strategy and immune monitoring across our clinical immunotherapy programs. This role will focus on characterization of treatment-induced immune responses, pharmacodynamic biomarkers, and translational correlates of clinical activity. The successful candidate will contribute to biomarker assay execution, data analysis, CRO oversight, and cross-functional translational efforts supporting clinical development. Responsibilities: Support immunomonitoring strategies across oncology clinical trials Coordinate biomarker sample collection, processing, tracking, and vendor execution for PBMCs, blood, serum/plasma, and tumor tissue Execute and oversee biomarker assays, including: multiparameter flow cytometry ELISpot / FluoroSpot intracellular cytokine staining T-cell functional assays multiplex cytokine profiling humoral immune response assays tumor immune profiling (preferred) Analyze immunologic and biomarker datasets to assess treatment-related immune responses and pharmacodynamic activity Support external CRO/vendor management, assay troubleshooting, and data review Collaborate with Clinical Development, Clinical Operations, Research, Regulatory, etc Prepare presentations, reports, and scientific summaries for internal review Qualifications: Required: PhD in Immunology, Cancer Biology, Molecular Biology, or related field OR MS with 3–6 years of relevant biotech experience Strong background in immunology and immune monitoring Hands-on experience with flow cytometry, PBMC handling, ELISpot, and functional immune assays Experience analyzing human translational or clinical biomarker data Strong organizational and analytical skills Comfortable working collaboratively in a team-oriented environment, with the ability to communicate effectively and contribute positively across functions. Preferred: Experience in immuno-oncology or oncology clinical development Familiarity with cancer vaccines, cell-based immunotherapies, or checkpoint inhibitor combinations Experience with CRO oversight and clinical biomarker workflows Knowledge of FlowJo, GraphPad Prism, and basic biomarker data analysis tools Equal Employment Opportunity Statement BriaCell is an Equal Opportunity Employer. We are committed to providing equal employment opportunities to all employees and applicants for employment without regard to race, color, religion, sex, pregnancy, sexual orientation, gender identity or expression, national origin, age, disability, genetic information, veteran status, marital status, or any other characteristic protected by applicable federal, state, or local law. Third-Party Agency Statement BriaCell does not accept unsolicited resumes or candidate submissions from search firms, staffing agencies, or other third-party recruiters without a signed agreement in place. Any unsolicited resumes submitted to BriaCell, its employees, or hiring managers will be considered the property of BriaCell, and no fees will be paid in the event the candidate is hired. #J-18808-Ljbffr BriaCell Therapeutics Corp.